Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) Restructuring Costs (2020 - 2026)

Bioventus filings provide 5 years of Restructuring Costs readings, the most recent being -$52000.0 for Q4 2024.

  • On a quarterly basis, Restructuring Costs rose 26.76% to -$52000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$52000.0, a 106.19% decrease, with the full-year FY2025 number at $2.2 million, up 4398.08% from a year prior.
  • Restructuring Costs hit -$52000.0 in Q4 2024 for Bioventus, up from -$71000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $4.6 million in Q4 2022 to a low of -$71000.0 in Q4 2023.
  • Median Restructuring Costs over the past 5 years was $576000.0 (2022), compared with a mean of $884750.0.
  • Biggest five-year swings in Restructuring Costs: skyrocketed 570.54% in 2022 and later crashed 104.52% in 2023.
  • Bioventus' Restructuring Costs stood at $563000.0 in 2020, then increased by 22.38% to $689000.0 in 2021, then skyrocketed by 570.54% to $4.6 million in 2022, then plummeted by 101.54% to -$71000.0 in 2023, then rose by 26.76% to -$52000.0 in 2024.
  • The last three reported values for Restructuring Costs were -$52000.0 (Q4 2024), -$71000.0 (Q4 2023), and -$26000.0 (Q3 2023) per Business Quant data.